Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
John M DennisWilliam E HenleyMichael N WeedonMike LonerganLauren R RodgersAngus G JonesWilliam T HamiltonNaveed SattarSalim JanmohamedRury R HolmanEwan R PearsonBeverley M ShieldsAndrew T Hattersleynull nullPublished in: Diabetes care (2018)
Patient subgroups defined by sex and BMI have different patterns of benefits and risks on thiazolidinedione and sulfonylurea therapy. Subgroup-specific estimates can inform discussion about the choice of therapy after metformin for an individual patient. Our approach using routine and shared trial data provides a framework for future stratification research in type 2 diabetes.
Keyphrases
- cell therapy
- type diabetes
- stem cells
- phase iii
- mesenchymal stem cells
- body mass index
- case report
- electronic health record
- study protocol
- clinical practice
- clinical trial
- glycemic control
- cardiovascular disease
- human health
- big data
- insulin resistance
- weight gain
- metabolic syndrome
- machine learning
- decision making
- weight loss